MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
ePoster Gallery
GPP006: Multi-Sample Approach for Breast Cancer Prognostic Biomarkers via Microbiome Profiling
Jeongshin An MD, PhD, Professor
Institute of Convergence Medicine Research, Ewha Womans University Mokdong Hospital, College of Medi
GPP008: Awareness of hereditary breast cancer and genetic testing among patients with breast cancer in Nigeria: A multi-centre study
Funmilola Wuraola MBBS, ChM
Department of Surgery, Faculty of Clinical Sciences, Obafemi Awolowo University Ile-Ife, Nigeria Af
GPP009: Evaluation of the expression of soluble coestimulatory molecules of lymphocute activation sOX40, sOX40L, s4-1BB and sICOS in Gastric Cancer
Cecilia Lima MD
Hospital Israelita Albert Einstein
P001: Activated Hippo pathway is associated with worse response to Trastuzumab and survival in HER2-positive breast cancer
Masanori Oshi
Roswell Park Comprehensive Cancer Center
P001: Addressing Global Inequities in Breast Cancer Genetic Testing, Counselling, and Management Among Breast Cancer Patients in Nigeria
Colleen Kerrigan MD
Department of Surgery, University of Toronto
P002: Application of Choosing Wisely Recommendations to Axillary Management in Early-Stage HR+/HER2- Local Breast Recurrences
Eliza Lorentzen MD
Brigham and Women's Hospital/Dana-Farber Brigham Cancer Center
P003: Association between 21-gene Recurrence Score and Racial Differences in Chemotherapy in Premenopausal Breast Cancer
Sara Myers
The Ohio State University Wexner Medical Center/ The James
P004: Associations Between Language and Barriers to Care on Self-Reported Stress in Hispanic Breast Cancer Patients
Maria Sierra MD, MPH
University of Miami Miller School of Medicine
P005: Axillary Management in the Setting of Multicentric/Multifocal Breast Cancer: ACOSOG Z0011 Implications
Elizabeth Fish D.O.
Fox Chase Cancer Center
P006: Clinical Relevance of Sphingosine 1-Phosphate Receptor 4 (S1PR4) in Breast Cancer Using Bulk and Single-Cell Transcriptome Analysis
Sarah McIntyre MD
Roswell Park Comprehensive Cancer Center
P007: The Impact of Clinical Stage at Presentation on Overall Survival in Patients with HER2 Positive Breast Cancer Treated with Neoadjuvant Chemotherapy
Nara Tashjian MD, MBA
Mayo Clinic
P008: Closing the Gap: A longitudinal review of the trends of gender representation in the Society of Surgical Oncology committee membership and annual meeting presenters from 2010 to 2023
Natalie Gaughan MD
Medical College of Wisconsin
P009: Differential responses to neoadjuvant chemotherapy in non-BRCA1 genetic breast cancers
Avia Wilkerson MD, PhD
Cleveland Clinic - Cleveland, OH
P010: Evaluation of axillary management strategies for occult malignancy in contralateral prophylactic mastectomy
Christopher Vetter MD, MSc
Mayo Clinic
P011: Genetic testing and impact on surgical management of breast cancer in the setting of new society guidelines
Christina Rutherford BA
P012: Hospitalizations and emergency visits in breast cancer patients undergoing neoadjuvant chemotherapy with pembrolizumab: A population-based analysis
Gary Ko MD, MSc
University of Toronto
P014: Impact of mastectomy versus lumpectomy on mortality in patients with T4b breast cancer
Maha Marshad
University of Toronto
P015: Importance of FDG PET/CT in early prediction of response to neoadjuvant chemotherapy in breast cancer patients: A tertiary care cancer center experience from India
Jeewan Vishnoi Additional Professor & Head, Department of Surgical Oncology
All India Institute of Medical Sciences